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Costs, Benefits, and Risks on the
Pathway to Malaria Elimination
Following a decade of gains in malaria
control, two divergent prospects are emerg-
ing: malaria elimination in many endemic
countries, and spreading artemisinin-resis-
tant P. falciparum undermining these
gains. The potential benefits of malaria
elimination are substantial, including the
direct burden averted and economic
growth through improved educational at-
tainment and productivity; these gains were
estimated recently to far outstrip the costs
required to achieve them [1].
Much of the international investment in
malaria control, approximating US$2.5
billion annually, is allocated to distributing
insecticide treated nets (ITN) and im-
proved diagnosis and treatment of clinical
cases. While these contributed to the
declining burden of malaria, avoiding the
spread of artemisinin resistance and a final
push to elimination could require addi-
tional interventions, notably population-
wide antimalarial treatment.
There is a qualitative difference be-
tween interventions such as ITN and
improved case management, offering im-
mediate health gains to recipients, and the
treatment of asymptomatic, often unin-
fected individuals for a broader commu-
nity gain, which offers little or no direct
benefit and may even harm recipients. An
unfavourable individual risk/benefit ratio
could deter both policy makers from
adopting what could be a critical compo-
nent of an effective elimination campaign,
and health providers from supporting its
effective implementation.
Mass drug administration (MDA) could,
however, be essential to malaria elimina-
tion. This is because of the substantial
proportion of malaria infections that are
asymptomatic and chronic at densities
lower than detection thresholds for micros-
copy or malaria rapid tests, even in areas of
low malaria transmission. These infections
still produce gametocytes, and in low-
endemic settings are estimated to account
for 20%–50% of transmission episodes [2–
6]. Targeting asexual parasites in these
carriers using drugs such as artemisinin
combination therapies will limit de-novo
gametocyte development but will not kill
gametocytes already present. An MDA
which includes a gametocytocidal drug
might therefore be more effective than
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Summary Points
N Rapidly achieving falciparum malaria elimination could require mass antima-
larial treatment of asymptomatic individuals to eliminate the parasite reservoir
that sustains malaria transmission.
N Primaquine is the only licenced antimalarial that kills mature Plasmodium
falciparum gametocytes, but it is associated with a dose-dependent risk of
haemolysis in G6PD-deficient individuals.
N We discuss ethical and economic considerations pertaining to mass primaquine
administration in malaria elimination programmes, which go beyond those
encountered in other public health interventions. These include the lower direct
benefit for individuals at higher risk, the increasingly available diagnostic tests
for G6PD deficiency, and the economic implications of testing.
N We propose a research agenda to assist informed and rational policy decision
making in the rollout of primaquine mass drug administration that is
pragmatically and economically viable and within acceptable ethical standards.
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one which does not. High coverage would
be key to its success.
Primaquine is the only licenced antima-
larial that kills mature P. falciparum
gametocytes, but safety concerns in indi-
viduals with glucose-6-phosphate dehydro-
genase deficiency (G6PDd) have deterred
its use to interrupt transmission on a large
scale [3,5,7]. The X-linked G6PDd has
gene frequencies ranging from 3% to 30%
in malaria-endemic areas and causes dose-
dependent haemolysis following adminis-
tration of primaquine or other oxidant
drugs [8].
Over two hundred million people have
received primaquine, but in the majority
of cases primaquine was given in a two-
week course (0.25 mg base/kg/day) to
prevent relapses of vivax malaria. This
carries a substantially greater risk than
single-dose administration to prevent
transmission of falciparum malaria. Ex-
cluding Chinese data for which denomi-
nators are unclear, it has been estimated
that the risk of death associated with use of
primaquine is one in 621,428 individuals
treated, with an upper 95% CI boundary
of one in 407,807 [9]. A review of
primaquine MDA aiming for vivax elim-
ination found very few reported incidences
of severe adverse events following multiple
primaquine doses [10]. The highest rate
was in Azerbaijan where, despite a high
prevalence of severe G6PDd variants, only
seven out of 30,000 individuals treated had
a severe adverse event, none of whom
required hospitalization. Only one death
has been reported following a single dose
of primaquine to block P. falciparum
transmission, and there have been occa-
sional reports of significant haemolysis
following the 0.75 mg base/kg gametocy-
tocidal dose hitherto recommended. The
WHO recently adjusted its guidelines for
the management of falciparum malaria in
low-transmission settings to allow for a
single, low dose of primaquine (0.25 mg
base/kg) without G6PDd testing, except
for pregnant women and infants ,1 year
of age [11]. This was considered highly
unlikely to induce clinically significant
haemolysis even in severely G6PD-defi-
cient individuals, concluding that the
transmission-blocking benefit outweighed
the associated risk. The effectiveness of
adding a single low-dose primaquine to
MDA depends on several factors, and, in
settings where the other drugs are highly
effective and coverage is very high, it
would add little. This Essay assumes that
this addition would be effective and
examines the ethical and economic argu-
ments for and against the use of prima-
quine and G6PD testing in MDA.
Unique Challenges in Use of
Primaquine as a P. falciparum
Gametocytocide in MDA
Previous public health interventions,
such as the smallpox and polio eradication
campaigns, posed comparable risks to
vaccinated individuals, as does the use of
sulfadoxine–pyrimethamine and other an-
timalarials in intermittent preventive treat-
ment often provided to children and
pregnant women in malaria-endemic re-
gions [12–14]. The use of primaquine in
MDA introduces additional unique chal-
lenges in several important respects. In
terms of the risks involved, compared with
smallpox and eradication campaigns, a
failed MDA programme could cause sig-
nificant harm if it contributed to emerging
drug resistance and a resurgence of malaria
in populations with lowered immunity.
Ethically, there are two additional aspects
that make use of primaquine as a P.
falciparum gametocytocide in MDA con-
tentious. Firstly, the use of primaquine offers
no curative or prophylactic effect to the
individuals receiving it (other than the
indirect benefit of reducing the likelihood
of future malaria), but it does expose them to
risk of harm (albeit substantially less than
with higher doses, or with longer courses as
used to eliminate P. vivax). Asymptomatic
carriers targeted by the programme are less
likely to benefit from the programme
because of their immunity to malaria.
Secondly, the technology to identify
G6PD-deficient individuals and exclude
them from treatment is increasingly avail-
able. While intuitively appealing, this
involves significant trade-offs – it would
lower gametocytocidal treatment coverage,
jeopardising the campaign and therefore
increasing the probability of a rebound in
malaria cases; and it requires significant
resources to prevent what is likely be a very
low degree of harm. Assuming a cost of
US$2 per test, the above estimated mortal-
ity of 1–2 million, and a life expectancy of
20 years, would result in a cost per DALY
averted in the range of US$50,000 to
US$100,000, far exceeding what is normal-
ly considered cost-effective in low-income
settings. The substantially lower estimated
risk associated with single-dose primaquine
would imply an even higher cost per DALY
averted. This investment, from a conse-
quentialist perspective, might be unethical,
if these resources could be used elsewhere
to generate far greater health benefits; but
from other ethical perspectives and given
the unique context, use of the tests could
still be considered an ethical obligation.
Taken together, the decision to imple-
ment MDA with primaquine introduces
challenges both within public health ethics
and between public health ethics and
those of clinical practice [15,16].
The Public Health Perspective
At the core of public health ethics is the
ambition of improving the health of popula-
tions whilst minimising potential risks to the
liberty or autonomy of individuals [14]. A
simple ‘‘back of the envelope’’ consequenti-
alist assessment suggests that, on average, the
risk of malaria mortality in low-transmission
settings is at least several hundred-fold that of
a fatal adverse event following low-dose
primaquine (based on the 2012 World
Malaria Report annual malaria mortality
rate of 0.02% in endemic areas and an
estimated risk of primaquine-induced mor-
tality equal to or lower than 1–2 per million,
derived largely from the higher dosages used
for the radical cure of vivaxmalaria [9,10]). It
is important to note that for vivax malaria the
risk/benefit ratio of primaquineMDAwill be
very different, as although there may be
individual benefit from prevention of relapse,
the required primaquine dose and the
associated risk is much higher, while the risks
associated with vivax malaria are lower, in
which case the consequentialist assessment
will be far less favourable.
Despite a favourable consequentialist
assessment, an unequal distribution of risk
amongst different ethnic groups and mar-
ginalized communities with poorer access to
medical care tomanage adverse events poses
further challenges. The confluence of ma-
laria transmission, marginalized communi-
ties, and in some instances higher prevalence
of G6PDd is a reality inmany endemic areas
[17]. Central government and international
public health officials will have to ensure a
balanced approach that does not infringe on
individual and community rights when
pursuing high coverage, as was reportedly
the case in the final stages of smallpox
eradication [18]. Maintaining trust between
the public and health-care workers should
remain a priority. The potential for per-
ceived serious adverse events in healthy
individuals, whether or not they are truly
related to the drug, could jeopardise this
relationship.
From the public health planners’ perspec-
tive, the question of consent on the part of
recipient communities is paramount. There
is a distinction between medical research,
which usually necessitates an opt-in in-
formed consent process, and public health
interventions where an opt-out approach
might be more appropriate [19]. In extreme
(and contentious) instances it has even been
considered acceptable to take compulsive
measures to avoid the spread of infectious
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diseases, such as interning tuberculosis
patients to complete their treatment [20].
The spread of artemisinin-resistant P.
falciparum to India and Africa could
undermine the recent global gains inmalaria
morbidity and mortality [21]. Stopping it
should have the highest priority. There are
compelling reasons, however, for strong
community engagement programmes that
seek to achieve community awareness and
approval for MDA. From an ethical stand-
point, given the absence of individual
immediate benefit from the primaquine
component and the potential harm, in-
formed community and individual consent
is particularly relevant. Furthermore, from a
pragmatic perspective it will be impossible to
achieve the required high coverage without
strong local support.
In considering these challenges, reference
should be made to relevant national and
international legal frameworks and ethics
guidelines. Such laws, embedded in national
constitutions and legislative mechanisms, as
well as conventions and customary obliga-
tions under international law, guarantee
specific legal entitlements to individuals
subjected to medical interventions, even
where these are at the expense of the ‘‘greater
good’’ [22].
The Health-Care Provider
Perspective
Although health providers administer-
ing treatments in an MDA programme
might be committed to reducing malaria
transmission in the population, their
primary concern is likely to be the well-
being of individuals in their care. Indeed,
health-care professionals have a legal and
moral duty to act in the best interests of
the patient. In practical terms, this means
that health-care professionals exercising
their duty of care will generally administer
medication only where the risk of harm is
minimal or where the individual benefit
outweighs the risk of harm [23].
This is prima facie at odds with the
administration of a potentially harmful drug
to an asymptomatic or even uninfected
individual for the benefit of the wider
community. Much depends, however, on
the degree of risk involved. For therapeutic
interventions the obligation to ensure in-
formed consent is proportional to the risk
involved [24,25]; in a public health context it
could be contended that disclosure require-
ments should be higher, especially where
there is no direct health benefit. Assuming a
community engagement programme has
adequately informed recipients of the risks
and benefits involved, a key question from the
provider perspective remains the extent to
which consent from the recipient (implicit or
explicit) provides sufficient normative
justification to administer the intervention.
From their perspective consent on behalf of
the recipient is necessary but not in itself
sufficient to act in accordance with clinical
ethics [25], unless they are equally convinced
the benefits outweigh the risks. Engagement
of health-care providers in the planning and
execution of the programmes to ensure their
support is therefore imperative.
Even if implicit informed consent is
normatively acceptable, ensuring its validity
will be challenging. Will individuals com-
prehend the difference between a public
health intervention and an individual cura-
tive treatment [26]?Will they find it difficult
to object to such treatment, either because
they are grateful to, or overly respectful
towards, health-care providers? Will peer
pressure place undue influence on them,
particularly if it is understood that refusal to
participate could jeopardise the initiative for
which others have accepted the risk? These
questions are of particular concern amongst
marginalized communities.
Possible Ways Forward
Considering these challenges, how best to
proceed? One option is to continue minimis-
ing the burden of clinical cases without
pushing forward with an aggressive elimina-
tion campaign. This will spare the resource-
intensive phase required in stamping out final
infections and avoiding re-importation, as
well as potential harm associated with
measures such as primaquine MDA. The
risk here is that the spread of artemisinin
resistance undermines our ability to effective-
ly treat clinical cases coupled with a rebound
in transmission, resulting in a large increase in
morbidity and mortality. The global im-
pact could be enormous.
With a more ambitious objective of
interrupting transmission, an alternative
strategy targeting asymptomatic infections
and circumventing the ethical challenges in
MDA is to screen for parasitaemia and treat
only positive individuals, offering a clearer
benefit to drug recipients. The malaria tests
available for wide-scale screening, however,
often fail to identify low levels of parasitaemia
[27]. As such, a large proportion of asymp-
tomatic carriers – the primary target of this
intervention – would be missed, potentially
rendering the programme ineffective.
Given these limitations, MDA with single
dose primaquine might be the only option
for successful elimination campaigns. The
risk associated with this low dose is small,
even in G6PD-deficient individuals, and
while its existence raises ethical questions
both in relation to public health and to
clinical care, these can be managed with
careful consideration. On this basis it is our
view that MDA programmes that include
the use of primaquine are justifiable, but will
require carrying out a significant pro-
gramme of research together with imple-
mentation (see Box 1). A research and
implementation agenda for primaquine
Box 1. A Research Agenda Prior to Policy Decisions on Rolling
Out Primaquine MDA
1. A number of MDA studies with single-dose primaquine and other drug
regimens have been carried out or are underway; further studies are needed to
inform on the impact on transmission and establish the regimens’ safety profiles
in different age groups and in G6PD normal and deficient subgroups.
2. These findings can be used in economic–epidemiological models to estimate
the costs and benefits of MDA with or without gametocytocidal drugs and the
probability and timeframe to elimination. Such models can also estimate the
minimal coverage required for successful elimination, and explore the impact of
excluding G6PD-deficient individuals from gametocytocidal treatment.
3. If exclusion of G6PD-deficient individuals is predicted to critically compromise
the programme’s effectiveness or the cost is prohibitive, further assessment
should be undertaken to explore whether provision of primaquine without
G6PD testing would comport with national and international legal obligations
and comply with ethical standards.
4. Qualitative research is required to provide insight into the practical ethical
challenges that may arise for health professionals and for community members.
For example, it is important to understand community views about taking drugs
when ill and when not; attitudes towards Western medicine; and previous
experience with MDA programmes and any challenges associated with them.
5. Drawing on these findings, programme designs should be trialled to identify
those that achieve the highest levels of coverage while complying with ethical
and legal standards.
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MDA will require consideration of overall
societal benefit against the obligation to
protect individuals and minority groups
from harm, as well as developing models
of good practice for ensuring effective
mechanisms for obtaining valid consent
and respecting the duty of care owed to a
patient by the health-care professional.
These measures should be considered not
only an ethical obligation, but a practical
necessity to ensure high levels of compli-
ance, key to the programmes’ success.
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